Immupharma PLC Notification of Interim Results (6933M)

TIDMIMM

RNS Number : 6933M

Immupharma PLC

20 September 2012

 
 FOR IMMEDIATE RELEASE   20 September 2012

ImmuPharma PLC

Notification of Interim Results

Date: Wednesday 26 September 2012

ImmuPharma PLC (AIM:IMM), the specialist discovery and development pharmaceutical company, is scheduled to announce its Interim Results for the six months ended 30 June 2012 on Wednesday 26 September 2012.

For analysts who would like an update meeting with ImmuPharma's management team following the announcement of the results, please contact Lisa Baderoon, Head of Investor Relations, at the contact details given below.

Ends

For further information, please contact:

 
 ImmuPharma plc                           + 44 (0) 20 7152 4080 
 Dimitri Dimitriou, Chief Executive 
  Officer                                 + 44 (0) 20 7152 4080 
 Richard Warr, Chairman 
 Lisa Baderoon, Head of Investor 
  Relations 
  lisa.baderoon@immupharma.com             + 44 (0) 7721 413496 
 
 Buchanan                                 + 44 (0) 20 7466 5000 
 Mark Court 
 
 Panmure, Gordon & Co., NOMAD & 
  Broker                                   +44 (0) 20 7459 3600 
 Andrew Burnett 
 Fred Walsh 
 
 Espirito Santo Investment Bank, 
  Joint Broker                             +44 (0) 20 7456 9191 
 James Bromhead 
 Richard Crawley 
 
 Cenkos Securities plc, Joint Broker       +44 (0) 20 7397 8900 
 Stephen Keys, Camilla Hume (Corporate 
  Finance) 
 Andy Roberts (Sales)

This information is provided by RNS

The company news service from the London Stock Exchange

END

NORFKLLFLKFBBBL

Immupharma (LSE:IMM)
Historical Stock Chart
From Jun 2024 to Jul 2024